Cutaneous adverse effects associated with LAG‐3 inhibitor use in cancer treatment: A systematic review

Immunotherapy has become a mainstay of treatment for many cancers. Multiple immune checkpoint inhibitors have been used to treat malignancies, including anti‐programed death‐1 (PD1) and anti‐cytotoxic T‐lymphocyte‐associated protein (anti‐CTLA4). However, a significant percentage of patients develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghani, Hira, Khan, Samavia, Jamgochian, Marielle, Richards, Beth, DeCecco, Erica, Fliorent, Rebecca, Cheendalla, Nithisha, Khatri, Khalil, Rao, Babar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690694/
https://www.ncbi.nlm.nih.gov/pubmed/38047262
http://dx.doi.org/10.1002/ski2.296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690694/
https://www.ncbi.nlm.nih.gov/pubmed/38047262
http://dx.doi.org/10.1002/ski2.296

Ejemplares similares